SEC Form 4 · accession 0001114220-17-000028
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Enyedy
Director
Period of report
Sep 11, 2017
Accepted (ET)
Sep 13, 2017 · 8:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F1 | $7.32 | Sep 11, 2017 | A | 50,000 | A | Sep 11, 2018 | Sep 11, 2027 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The 50,000 stock options vest as follows: 16,667 on September 11, 2018; 16,667 on September 11, 2019; 16,666 on September 11, 2020.